These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23990111)

  • 1. Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up.
    Melis M; Cocco E; Frau J; Lorefice L; Fenu G; Coghe G; Mura M; Marrosu MG
    Neurol Sci; 2014 Mar; 35(3):401-8. PubMed ID: 23990111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significant clinical worsening after natalizumab withdrawal: Predictive factors.
    Vidal-Jordana A; Tintoré M; Tur C; Pérez-Miralles F; Auger C; Río J; Nos C; Arrambide G; Comabella M; Galán I; Castilló J; Sastre-Garriga J; Rovira A; Montalban X
    Mult Scler; 2015 May; 21(6):780-5. PubMed ID: 25392320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natalizumab is effective in multiple sclerosis patients switching from other disease modifying therapies in clinical practice.
    Lanzillo R; Bonavita S; Quarantelli M; Vacca G; Lus G; Amato L; Carotenuto A; Tedeschi G; Orefice G; Brescia Morra V
    Neurol Sci; 2013 Apr; 34(4):521-8. PubMed ID: 22526763
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis.
    Khalid F; Tauhid S; Chua AS; Healy BC; Stankiewicz JM; Weiner HL; Bakshi R
    Int J Neurosci; 2017 May; 127(5):396-403. PubMed ID: 27143245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of rebound effect after natalizumab withdrawal in multiple sclerosis. Study of two high-dose methylprednisolone schedules.
    Fuentes-Rumí L; Hernández-Clares R; Carreón-Guarnizo E; Valero-López G; Iniesta-Martinez F; Cabrera-Maqueda JM; León-Hernández A; Zamarro-Parra J; Morales-Ortiz A; Meca-Lallana JE
    Mult Scler Relat Disord; 2020 Sep; 44():102311. PubMed ID: 32593958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natalizumab therapy for highly active pediatric multiple sclerosis.
    Kornek B; Aboul-Enein F; Rostasy K; Milos RI; Steiner I; Penzien J; Hellwig K; Pitarokoili K; Storm van's Gravesande K; Karenfort M; Blaschek A; Meyer A; Seidl R; Debelic D; Vass K; Prayer D; Kristoferitsch W; Bayas A
    JAMA Neurol; 2013 Apr; 70(4):469-75. PubMed ID: 23420110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment effect of natalizumab on relapse outcomes in multiple sclerosis patients despite ongoing MRI activity.
    Bates D; Bartholomé E
    J Neurol Neurosurg Psychiatry; 2012 Jan; 83(1):55-60. PubMed ID: 21865211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exposure-disease response analysis of natalizumab in subjects with multiple sclerosis.
    Muralidharan KK; Steiner D; Amarante D; Ho PR; Mikol D; Elkins J; Subramanyam M; Nestorov I
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):263-275. PubMed ID: 28251386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study.
    Sousa L; de Sa J; Sa MJ; Cerqueira JJ; Martins-Silva A;
    Rev Neurol; 2014 Nov; 59(9):399-406. PubMed ID: 25342053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
    Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
    Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.
    Fox RJ; Cree BA; De Sèze J; Gold R; Hartung HP; Jeffery D; Kappos L; Kaufman M; Montalbán X; Weinstock-Guttman B; Anderson B; Natarajan A; Ticho B; Duda P;
    Neurology; 2014 Apr; 82(17):1491-8. PubMed ID: 24682966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
    Havla J; Tackenberg B; Hellwig K; Meinl I; Krumbholz M; Seitz F; Eienbröker C; Gold R; Hohlfeld R; Kleiter I; Kümpfel T
    J Neurol; 2013 May; 260(5):1382-7. PubMed ID: 23266894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study.
    Barbin L; Rousseau C; Jousset N; Casey R; Debouverie M; Vukusic S; De Sèze J; Brassat D; Wiertlewski S; Brochet B; Pelletier J; Vermersch P; Edan G; Lebrun-Frenay C; Clavelou P; Thouvenot E; Camdessanché JP; Tourbah A; Stankoff B; Al Khedr A; Cabre P; Papeix C; Berger E; Heinzlef O; Debroucker T; Moreau T; Gout O; Bourre B; Créange A; Labauge P; Magy L; Defer G; Foucher Y; Laplaud DA;
    Neurology; 2016 Feb; 86(8):771-8. PubMed ID: 26826205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
    Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study.
    O'Connor P; Goodman A; Kappos L; Lublin F; Polman C; Rudick RA; Hauswirth K; Cristiano LM; Forrestal F; Duda P
    Neurology; 2014 Jul; 83(1):78-86. PubMed ID: 24898925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL.
    Hutchinson M; Kappos L; Calabresi PA; Confavreux C; Giovannoni G; Galetta SL; Havrdova E; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Rudick RA; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    J Neurol; 2009 Mar; 256(3):405-15. PubMed ID: 19308305
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
    van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C
    Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of natalizumab in patients with highly active relapsing remitting multiple sclerosis.
    Cobo-Calvo Á; Bau L; Matas E; Romero-Pinel L; Mañé Martínez MA; Majós C; Martínez Yélamos S
    Eur Neurol; 2015; 73(3-4):220-229. PubMed ID: 25792347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical baseline factors predict response to natalizumab: their usefulness in patient selection.
    Laroni A; Gandoglia I; Solaro C; Ribizzi G; Tassinari T; Pizzorno M; Parodi S; Baldassarre G; Rilla MT; Venturi S; Capello E; Sormani MP; Uccelli A; Mancardi GL
    BMC Neurol; 2014 May; 14():103. PubMed ID: 24885703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.